Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis

Table 1 Study characteristics

Ref.	Country	Date	Type	n	NOS (0-9)	Pre-operative infliximab use (w)	Age1	Sex (m)	Steroids	Abscess
Appau et al[7]	United States	1998-2007	Retrospective cohort	389	7	12
Infliximab							35.8 (11.9)	48.3%	65%	38%
No infliximab							36.8 (14.4)	45.9%	77%	44%
Canedo et al[10]	United States	2000-2008	Retrospective cohort	225	7	12
Infliximab							26 (24.9-43.6)	44%	NS	37%
No infliximab							32 (29.4-41.9)	51%	NS	30%
Colombel et al[11]	United States	1998-2001	Retrospective cohort	270	7	8
Infliximab							NS	NS	36%	NS
No infliximab							NS	NS	42%	NS
El Hussuna et al[17]	Denmark	2000-2007	Retrospective cohort	369	7	12
Infliximab							33 (18-62)	NS	NS	34%
No infliximab							37 (8-90)	NS	NS	19%
Kasparek et al[15]	Munich	2001-2008	Case control match	96	7	12
Infliximab							35 (17-66)	43%	94%	NS
No infliximab							39 (17-68)	50%	94%	NS
Kotze et al[23]	Brazil	2007-2010	Retrospective cohort	76	7	4
Infliximab							NS	NS	NS	NS
No infliximab							NS	NS	NS	NS
Marchal et al[18]	Netherlands	1998-2002	Case control match	68	8	12
Infliximab							36 (16-73)	NS	35%	50%
No infliximab							38.7 (17-63)	NS	35%	41%
Mascarenhas et al[16]	United States	2003-2010	Retrospective cohort	93	6	12
Infliximab							35.6 (14.1)	42%	68%	NS
No infliximab							37 (14.1)	60%	44%	NS
Myrelid et al[21]	Europe	1989-2002	Retrospective cohort	298	6	8
Infliximab							NS	46%	NS	20%
No infliximab							NS	36%	NS	20%
Nasir et al[20]	United States	2005-2008	Retrospective cohort	370	8	8
Infliximab							38.2 (17-66)	43%	31%	NS
No infliximab							43.3 (17-77)	41%	45%	NS
Nørgård et al[9]	Denmark	2000-2010	Retrospective cohort	2293	6	12
Infliximab							NS	45%	9%	NS
No infliximab							NS	41%	14%	NS
Syed et al[8]	United States	2004-2011	Retrospective cohort	325	7	8
Infliximab							38.2 (13.9)	34%	40%	8%
No infliximab							40 (14.3)	45%	35%	9%
Tay et al[19]	United States	1998-2002	Retrospective cohort	100	7	8
Infliximab							NS	NS	0%	NS
No infliximab							NS	NS	18%	NS
Uchino et al[22]	Japan	2008-2011	Retrospective cohort	405	7	12
Infliximab							36 (14-72)	73%	37%	NS
No infliximab							37 (16-78)	69%	34%	NS
Total				5377

¹Given as SD or range; NS: Not stated.

Table 2 Studies showing primary and secondary outcome measures

Ref.	Follow-up (d)	Anastomotic leak (%)	Abdominal sepsis (%)	Wound sepsis (%)	Total infectious complications (%)	Re-operation(%)	Mortality(%)
Appau et al[7]
Infliximab	30	10	10	0	40	8	1.6
No infliximab		4.2	4.3	0.3	21.5	3	0
Canedo et al[10]
Infliximab	30	5.7	3.1	13.8	21.5	3	NS
No infliximab		4.9	5	8.8	18.8	6	NS
Colombel et al[11]
Infliximab	30	NS	NS	NS	17.3	NS	0
No infliximab		NS	NS	NS	37	NS	0
El Hussuna et al[17]
Infliximab	30	9.4	NS	NS	NS	NS	1.35
No infliximab		12.7	NS	NS	NS	NS
Kasparek et al[15]
Infliximab	30	8.3	6.2	18.8	56.2	23	2.1
No infliximab		12.5	10.4	14.6	41.6	21	0
Kotze et al[23]	30
Infliximab		NS	10.5	NS	NS	NS	0
No infliximab		NS	15.8	NS	NS	NS	3
Marchal et al[18]
Infliximab	90	0	12.5	5	25	0	0
No infliximab		5.8	10.3	2.5	12.8	0	0
Mascarenhas et al[16]
Inflixmab	30	10.5	NS	10.5	NS	NS	0
No infliximab		4.1	NS	4.1	NS	NS	0
Myrelid et al[21]
Infliximab	30	7.2	NS	NS	23.4	8	NS
No infliximab		8	NS	NS	22	7	NS
Nasir et al[20]
Infliximab	30	3.4	NS	NS	NS	NS	0
No infliximab		2	NS	NS	NS	NS	0.79
Nørgård et al[9]
Infliximab	30	3.7	NS	NS	NS	7	0.46
No infliximab		2.7	NS	NS	NS	8	2.59
Syed et al[8]
Infliximab	NS	3.3	18.7	18.7	36	16	1.3
No infliximab		3.4	15.4	11.4	25	13	0.57
Tay et al[19]
Infliximab	30	4.5	9.1	NS	13.6	NS	NS
No infliximab		5.1	5.1	NS	10.2	NS	NS
Uchino et al[22]
Infliximab	30	NS	5.1	1.3	NS	NS	NS
No infliximab		NS	5.2	15.33	NS	NS	NS

NS: Not stated.